Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
GlobalData on MSN5d
Novo Nordisk plans new study for CagriSema, targets 2026 submissionCagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase ... is expected to launch in H1 2025, Martin Lange Novo’s (OTCPK:NONOF) executive vice president for development ...
Novo Nordisk defends its obesity drug CagriSema despite disappointing late-stage trial data that significantly affected its market value. The company plans a new trial in 2025 due to positive ...
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...
Martin Holst Lange, Novo Nordisk's head of development, pointed out that only 57% of patients had received the highest dose of CagriSema, asserting that the company remains "encouraged by the ...
The acquisition was announced on Monday with James Walker, CEO of Agostini’s Pharmaceutical Group, presents at MDJL’s Carifta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback